Skip to main content

Table 2 28-day PCR-unadjusted treatment efficacy of study children after treatment with Artesunate–amodiaquine or Artemether–lumefantrine

From: Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers

PCR-unadjusted outcome

Artesunate–amodiaquine

Artemether–lumefantrine

Bensonville (n = 91)

Saclepea (n = 89)

Kakata (n = 89)

Sinje (n = 90)

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

LCF

6 (8.3)

3.1–17.3

3 (3.4)

0.7–9.6

1 (1.2)

0.0–6.5

0 (0)

0.0–4.1

LPF

20 (27.8)

17.9–39.6

9 (10.2)

4.8–18.5

4 (4.8)

1.3–11.7

0 (0)

0.0–4.1

ACPR

46 (63.9)

51.7–74.9

76 (86.4)

77.4–92.8

79 (94.0)

86.7–98.0

88 (100)

95.9–100

Total per protocol

72

88

84

88

Withdrawn/lost

19 (20.9)

1 (1.1)

5 (5.6)

2 (2.2)

Kaplan Meier: cure rate

65.1

53.0–74.8

86.4

77.2–92.0

94.0

86.3–97.5

100

n/a

  1. LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response